Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedNov 14, 2025
DataAggregated Company Financials
Companies297
  • 7D7.3%
  • 3M21.6%
  • 1Y19.1%
  • YTDn/a

Over the last 7 days, the Pharma industry has risen 7.3%, driven by gains from Eli Lilly of 6.1%. In the last 12 months, the industry was up 19%. Earnings are forecast to grow by 13% annually.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 18 Nov 2025US$2.1tUS$402.8bUS$71.4b18x29.5x5.2x
Thu, 16 Oct 2025US$1.9tUS$389.2bUS$63.5b18.3x29.4x4.8x
Sat, 13 Sep 2025US$1.8tUS$387.9bUS$60.9b18.9x29.6x4.6x
Mon, 11 Aug 2025US$1.6tUS$387.9bUS$60.7b18.4x27x4.2x
Wed, 09 Jul 2025US$1.7tUS$382.7bUS$61.3b18x28.3x4.5x
Fri, 06 Jun 2025US$1.7tUS$382.7bUS$61.2b17.9x27.9x4.5x
Sun, 04 May 2025US$1.8tUS$382.7bUS$63.7b17.2x27.8x4.6x
Tue, 01 Apr 2025US$1.8tUS$380.6bUS$41.3b15.9x44.7x4.9x
Thu, 27 Feb 2025US$1.9tUS$381.2bUS$39.3b17.3x49.4x5.1x
Sat, 25 Jan 2025US$1.8tUS$370.4bUS$30.5b18.4x58.7x4.8x
Mon, 23 Dec 2024US$1.8tUS$369.4bUS$31.1b16.7x57.2x4.8x
Wed, 20 Nov 2024US$1.8tUS$373.8bUS$30.6b19.9x58x4.7x
Fri, 18 Oct 2024US$2.0tUS$365.3bUS$23.7b18.7x86x5.6x
Sun, 15 Sep 2024US$2.0tUS$364.3bUS$25.4b18.8x80.2x5.6x
Tue, 13 Aug 2024US$2.0tUS$362.1bUS$22.0b16.5x89.6x5.4x
Thu, 11 Jul 2024US$2.0tUS$357.6bUS$13.8b15.4x143.2x5.5x
Sat, 08 Jun 2024US$1.9tUS$358.3bUS$14.1b15.6x135.8x5.3x
Mon, 06 May 2024US$1.8tUS$358.0bUS$13.8b21.4x131.1x5.1x
Wed, 03 Apr 2024US$1.9tUS$355.2bUS$22.7b24.1x83.1x5.3x
Fri, 01 Mar 2024US$1.9tUS$355.2bUS$22.3b23.7x84.7x5.3x
Sun, 28 Jan 2024US$1.8tUS$375.2bUS$33.9b24.6x52.1x4.7x
Tue, 26 Dec 2023US$1.7tUS$375.1bUS$33.9b32x49.3x4.4x
Thu, 23 Nov 2023US$1.6tUS$375.1bUS$33.9b26x48.3x4.4x
Sat, 21 Oct 2023US$1.7tUS$382.7bUS$44.7b17.6x37x4.3x
Mon, 18 Sep 2023US$1.7tUS$381.8bUS$43.9b18x39.2x4.5x
Wed, 16 Aug 2023US$1.8tUS$381.7bUS$44.0b19.1x40.4x4.7x
Fri, 14 Jul 2023US$1.6tUS$392.8bUS$60.2b17.9x27.4x4.2x
Sun, 11 Jun 2023US$1.7tUS$393.0bUS$60.5b18.6x28.4x4.4x
Tue, 09 May 2023US$1.7tUS$395.2bUS$56.7b17.4x30.4x4.4x
Thu, 06 Apr 2023US$1.6tUS$401.2bUS$69.4b15.6x23.7x4.1x
Sat, 04 Mar 2023US$1.6tUS$401.2bUS$69.4b16.9x22.5x3.9x
Mon, 30 Jan 2023US$1.7tUS$402.6bUS$69.4b17.7x24x4.1x
Wed, 28 Dec 2022US$1.7tUS$403.7bUS$70.7b16.7x24.7x4.3x
Fri, 25 Nov 2022US$1.7tUS$403.7bUS$70.7b15.4x24.6x4.3x
Price to Earnings Ratio

24.6x


Total Market Cap: US$1.7tTotal Earnings: US$70.7bTotal Revenue: US$403.7bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 52.7x202320242025
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 29.5x which is lower than its 3-year average PE of 52.7x.
  • The 3-year average PS ratio of 4.7x is lower than the industry's current PS ratio of 5.2x.
Past Earnings Growth
  • Both revenue and earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
  • This means that sales and the cost of doing business have remained relatively consistent over this period and subsequently, so have profits.

Industry Comparison

How does U.S. Pharma compare with similar industries?

US Market-0.39%
Healthcare3.77%
Pharma7.30%
Pharma7.30%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$1.02k5.7%
+US$49.3b		40.5%PE49.7x
JNJ Johnson & JohnsonUS$199.585.9%
+US$26.9b		29.0%PE19.1x
MRK MerckUS$92.867.0%
+US$15.2b		-3.8%PE12.1x
PFE PfizerUS$25.082.8%
+US$3.9b		0.9%PE14.6x
JAZZ Jazz PharmaceuticalsUS$170.0927.7%
+US$2.2b		44.6%PS2.5x

Latest News

JNJ
US$199.58
Johnson & Johnson
7D
5.9%
1Y
29.0%
JAZZ
US$170.09
Jazz Pharmaceuticals
7D
27.7%
1Y
44.6%
TERN
US$25.56
Terns Pharmaceuticals
7D
33.7%
1Y
348.4%
ZTS
US$118.80
Zoetis
7D
-0.8%
1Y
-32.7%

ZTS: Earnings Will Rebound As Volume Pressures Ease In 2026

Zoetis' analyst price target has been reduced from approximately $188 to $171 per share, as analysts cite tempered growth expectations and revised financial assumptions following recent quarterly updates. Analyst Commentary Following Zoetis' latest quarterly updates and subsequent guidance revision, analysts have updated their perspectives on the company's outlook.
LLY
US$1,021.70
Eli Lilly
7D
5.7%
1Y
40.5%

LLY: Upcoming Drug Price Reductions and Policy Debates Will Shape Future Opportunities and Risks

The analyst price target for Eli Lilly has increased by over $80 to approximately $1,003 per share. Analysts point to accelerating revenue growth, higher profit margins, and ongoing strength in the company's obesity drug franchise as drivers of greater long-term value.
AVDL
US$23.02
Avadel Pharmaceuticals
7D
23.1%
1Y
114.8%
BMY
US$46.81
Bristol-Myers Squibb
7D
-1.0%
1Y
-17.6%
MRK
US$92.86
Merck
7D
7.0%
1Y
-3.8%
PFE
US$25.08
Pfizer
7D
2.8%
1Y
0.9%

PFE: Obesity Deal Will Drive Upside After Sector Underperformance And Portfolio Shifts

Pfizer’s analyst price target was raised from $28 to $30 per share, reflecting a modest increase in fair value. Analysts cite sector-wide re-rating and updated fundamentals, including acquisition activity and anticipated drug pipeline developments, as key drivers for the revision.
VTRS
US$10.66
Viatris
7D
4.8%
1Y
-18.0%

VTRS: Operational Discipline And Asset Management Will Guide Balanced Outlook Ahead

The analyst price target for Viatris was increased slightly from $12.00 to $12.13, as analysts cited improved revenue growth and higher profit margin expectations as key factors for the adjustment. Analyst Commentary Recent analyst opinions on Viatris reflect a balance between improving financial outlook and continued areas of caution.
ELAN
US$21.42
Elanco Animal Health
7D
-3.8%
1Y
59.3%
ANIP
US$81.97
ANI Pharmaceuticals
7D
-7.8%
1Y
48.4%

ANIP: Sustained Revenue Expansion Will Drive Momentum Amid Increasing Market Opportunities

Analysts have increased their average price target for ANI Pharmaceuticals from $105 to approximately $109.88, citing robust Cortrophin Gel performance, expanded market opportunities, and a strengthened revenue outlook. Analyst Commentary Industry analysts are closely monitoring ANI Pharmaceuticals following a series of price target increases.
LGND
US$201.35
Ligand Pharmaceuticals
7D
-3.8%
1Y
80.3%

LGND: Capital Flexibility And Business Model Will Shape Mid-Term Performance Outlook

Ligand Pharmaceuticals’ analyst price target has increased from $183.13 to $206.25. Analysts cite robust Q3 results and an ongoing strong business development model as key drivers for the upward revision.
TLRY
US$1.03
Tilray Brands
7D
-21.4%
1Y
-22.0%

TLRY: Progress On U.S. Rescheduling Will Unlock New Market Access

Tilray Brands has received an increased analyst price target from $1.50 to $2.00 per share, reflecting greater optimism because of anticipated regulatory changes and the company’s strong industry positioning. Analyst Commentary Bullish analysts have reacted positively to recent developments affecting Tilray Brands, noting a number of factors that could drive further growth and improve the company’s outlook.
BHC
US$6.13
Bausch Health Companies
7D
-4.2%
1Y
-26.8%
RGC
US$12.93
Regencell Bioscience Holdings
7D
-6.5%
1Y
7,344.6%